To investigate the role and possible targetability of DPP4 in human ovarian cancer patients to improve PARPi therapy, human DPP4 (hDPP4) expression was immunohistochemically analysed and semiquantitatively scored in 208 patients with high-grade serous ovarian cancer (HGSOC; Fig. 5a and Table S1). The gene discussed is DPP4; the disease is ovarian serous adenocarcinoma.